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Summary A lymphocyte clonal assay developed to quantitate in vivo somatic cell mutations at the
hypoxanthine-guanine phosphoribosyltransferase locus was modified in order to study resistance to
methotrexate. Even though nucleoside-free culture conditions were used methotrexate was not lethal to
lymphocytes plated into micro-wells at >102cells/well. HPLC analysis of supernatants from wells plated
initially with 104cells/well in lOO1pM methotrexate revealed the presence of micro-molar levels of
hypoxanthine and thymidine by the 5th and 8th day of culture respectively. When lymphocytes were plated at
102 cells/well in nucleoside free medium, methotrexate was cytotoxic and micro-molar levels of thymidine
together with hypoxanthine protected lymphocytes cultured under these conditions from toxicity. Modulation
of nucleic acid antimetabolite cytotoxicity by nucleosides and bases has been recognised for some years.
Nucleoside free culture conditions have been advocated for studying cellular sensitivity to antifolates to avoid
such interfering factors. However our results indicate that metabolites from dying or damaged cells can
prevent methotrexate cytotoxicity, further complicating the development of a suitable clonogenic assay for
investigating antifolate sensitivity.
The modulating effects of nucleosides on tumour growth
inhibition by antifolates have been recognised for many
years. A combination of thymidine (TdR) and hypoxanthine
(Hx) prevents methotrexate-induced lethality in normal and
malignant cells in vitro (Howell et al., 1981; Taylor &
Tattersall, 1981). In the human leukaemic cell line CCRF-
CEM, TdR or Hx alone partially protect from methotrexate
(MTX) induced growth inhibition (Taylor & Tattersall,
1981). In addition, exogenous purines can reduce or
potentiate methotrexate cytotoxicity in a variety of
mammalian cell lines, depending in part on the methotrexate
concentration (Taylor et al., 1982). Moreover differences in
nucleoside concentrations in commercial sources of calf and
horse serum can significantly influence the outcome of
studies of methotrexate interaction with other drugs (Piper et
al., 1983). For all these reasons the use of dialysed serum,
and TdR and purine free media has recently been advocated
to study MTX-induced cytotoxicity in clonogenic assays
(Sobrero & Bertino, 1986).
Clinical dogma maintains that acquired resistance to
cytotoxic drug treatment is extremely rare in normal cells but
a frequent development in tumour cells. The biological basis
for this apparent difference in frequency of development of
resistant phenotype between normal and tumour cells has
not been defined. However a clonal assay for human peri-
pheral blood lymphocytes (PBLs) has now been established
and somatic cell mutations at the hypoxanthine-guanine
phosphoribosyltransferase (EC2.4.2.8.) locus on the X-
chromosome have been measured using the purine analogue
6-thioguanine (6-TG) as the selecting agent (Morley et al.,
1985; Albertini et al., 1982). We have successfully established
this assay using 6-TG and have modified some aspects of
the culture conditions to enable us to use MTX successfully
as a selecting agent. Our results indicate that nucleosides and
bases released from cells dying during MTX treatment can
prevent cytotoxicity in surviving cells.
Materials and methods
Chemicals
TdR and Hx were purchased from Sigma Chemical Co., St.
Louis, MO, MTX was obtained from Cyanamid (Australia)
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Pty. Ltd., purified PHA (lots K7185 and K122410) from
Wellcome Reagents Laboratories (Australia); Interleukin-2
from Integrated Sciences (Australia); recombinant
Interleukin-2 from Amersham (Australia) and Ficoll-Paque
from Pharmacia (Australia). Purine bases and nucleosides
were purchased from either Boehringer-Mannheim
(Australia) Pty. Ltd., or Sigma. HPLC-grade methanol was
supplied by Waters Associates (Millipore, Australia).
Thymidine phosphorylase (EC 2.4.2.4) was purchased from
Calbiochem (Australia) and xanthine oxidase (EC 1.2.3.2)
from Boehringer-Mannheim.
Isolation and micro-well culture oflymphocytes
Mononuclear cells from single donor white cell concentrates
(Sydney Red Cross Blood Bank) or from normal volunteers
were sedimented on a Ficoll-Paque density gradient, washed
3 times with Dulbecco's phosphate buffered saline
(Ca2+ Mg2+-free, Commonwealth Serum Laboratories,
Australia) and finally resuspended in RPMI-1640
supplemented with L-glutamine (6mM), gentamicin sulphate
(0.5ugml-1), HEPES (20mM) and 15% v/v heat inactivated
(56°C, 30min) foetal bovine serum (FBS) (Flow
Laboratories, Australia) at 1-2 x l06 cellsml-. An aliquot
of cells was immediately irradiated with 5,000cGy (Cobalt
60y-rays, room temperature) for use as feeder cells.
Phytohaemagglutinin (PHA, 1 gml-1 culture) was added to
the remaining cells and these were used as target cells. Both
feeder and target cells were then incubated overnight at
37°C. Target PBLs were diluted appropriately for estimation
of cloning efficiencies (0-10cells/well) and drug (6-TG or
MTX) cytotoxicity (102 -2 x 104cells/well) in RPMI-1640
with normal FBS (NM) or dialysed FBS (DM). FBS was
dialysed extensively against 4 changes of NaCl solution
(9.0gl-1) followed by one change of Hank's balanced salt
solution (Flow Laboratories) over 3 days. The cells were
plated into round bottom 96 micro-well plates (Nunc,
Denmark) together with interleukin-2 (Integrated Sciences
IL-2 25HMUml-1 or Amersham recombinant IL-2
2.5HMUml-1) and PHA (1ugml-1) with or without 104
feeder cells/well giving a final volume of 0.2ml/well. Plates
were incubated at 37°C in a 10% CO2, 5% 02 humidified
atmosphere. Wells were either scored as positive or negative
following examination by inverted microscope after 10-14
days incubation, or contents harvested for counting during
this period. Viable cells were counted by haemocytometer
using phase-contrast microscopy. Cloning efficiencies were
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calculated using Poisson statistics and x2 minimisation
(Taswell, 1981). The frequency of spontaneous mutation to
resistance to 15,pM 6-TG was calculated from the ratio of
the cloning efficiencies in the presence and absence of 6-TG.
Bromodeoxyuridine (BrUdR) incorporation assay
The thymidine analogue BrUdR was added to each well to
give a final concentration of lOpM, 24h prior to harvest
(after 2, 5, 8 and 13 days incubation). Well cultures were
resuspended by aspiration with a 26G needle and syringe,
and the contents of duplicate wells were pooled and
centrifuged (200g) and 200p1 supernatant removed. The
remaining contents were resuspended and cytocentrifuged
(Shandon Elliott Cytospin; Cheshire, UK) onto glass slides.
Slides were fixed immediately in methanol:acetic acid (3:1)
and stored at room temperature prior to staining. Nuclei
that had incorporated BrUdR were visualised using immuno-
peroxidase amplification of a mouse monoclonal antibody
binding to BrUdR-substituted DNA, resulting in deposition
of brown pigment over positive cells (deFazio, 1987).
Haematoxylin was used as a counterstain. Where possible
over 400 nuclei were counted per slide.
HPLC analysis ofwell culture supernatants
Purine bases and nucleosides from deproteinised (Centricon
30 microconcentrators, Amicon Scientific, Australia) well
supernatants were separated using modifications of
Agarwal's methods (Agarwal, 1982). A Waters model
ALC/GPC-204 liquid chromatograph (Waters Associates)
was used incorporating a model 660 solvent programmer, a
model U6K universal injector, and a model 440 dual
wavelength detector (254 and 280nm) for obtaining
absorbance ratios. Two high pressure pumps (models 6000A
and M-45) delivered the eluent.
A guard column (30 by 4.6mm ID) packed with lOpm
LiChrosorb was used before an RP-18, lOpm column (250
by 4.5mm ID; Brownlee Lab Inc. Santa Clara CA). Initially
the eluents were lOmMKH2PO4, pH4.9 (solvent A) and
30% methanol in 10mM KH2PO4 (solvent B) and 40p1
aliquots of unknowns and standards were injected. A
gradient (2min of 10% B in A followed by 10-30% B in A
over 15min) separated peaks which were identified by their
absorbance ratios and retention times by comparison with
pure nucleoside and purine base standards. This method
allowed quantitative separation (in order of increasing
retention time) of uric acid 3.05, cytosine 3.49, Hx 4.23,
uridine 4.68, xanthine (X) 4.88, inosine 9.41, guanosine
10.41, deoxyinosine 11.34, TdR 13.67 and adenosine 20.73.
The identification of the TdR peak was confirmed by
enzymic peak-shift techniques using thymidine phosphorylase
and an isocratic run (5% methanol in solvent A) for greater
efficiency. Similarly the presence of Hx and X was confirmed
by digestion with xanthine oxidase using an isocratic run
(3% methanol in solvent A).
Results
Data obtained using the above culture conditions on 25
blood donations from 16 normal donors were comparable
with those published by others (Albertini et al., 1982; Morley
et al., 1983). PBL cloning efficiencies in the absence of
drugs varied from 20.6-53.75%, and the frequency of mutant
cells resistant to 15.0,pM 6-thioguanine ranged from
P.BX10-cut-r1.e X 1 N- 5.
PBLs cultured in NM in the presence of MTX 0.01-
100pM and 104 feeder cells/well showed reduction of colony
size rather than cytotoxicity. Figure 1 demonstrates the PBL
growth typically observed in NM cultures in the presence or
absence of 100 pM MTX. The rate of cell growth in the
absence of MTX was adversely affected by the highest initial
cell plating density. Wells plated with 102 or 103 cells
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Figure 1 PBL growth in NM in the presence ( ) or absence
of lOO1uM MTX in microwells plated initially with
different target cell numbers/well: *, 104; A, 103; *, 102. All
wells also had 104 feeder cells/well. Points, mean of duplicate
cultures.
showed a 30-fold increase in cell number over the period
whereas those plated with 104 cells only increased by 6-fold.
There was an unexpected relationship between the effect of
MTX on growth and the initial cell density. MTX had least
effect on growth in wells plated with 102 cells/well and most
effect on those plated with the highest number (104
cells/well). All MTX treated cultures reached similar viable
cell densities during the last days of incubation regardless of
the plating number initially.
When PBLs were plated at 104 cells/well in the presence or
absence of 104 feeder cells/well in NM or DM, no difference
in growth by day 14 in untreated cultures was observed
(Figure 2a). However in the presence of feeder cells MTX-
induced cell death by day 14 was reduced in both NM and
DM cultures (Figure 2a). In a similar experiment where
BrUdR was added to wells 24h prior to harvest, it was
apparent that even on the 5th day in 100pM MTX_45% of
cells were incorporating BrUdR ie synthesising DNA.
Cycling cells were observed whether cultured in NM or DM
and with or without feeder cells. By the 13th day in culture a
small percentage (5-16%) of cells incorporated BrUdR
during the 24h pulse period.
Feeder cells were necessary for growth with low initial
target cell numbers in either DM or NM (Figure 2b). When
the initial PBL number was reduced to < 102 cells/well,
growth in DM cultures was completely inhibited by MTX
(OOpM) in contrast to NM cultures (Figure 1 and 2b). As
growth was not inhibited maximally by MTX at the higher
initial cell densities, even in DM, MTX-treated culture
supernatants were analysed by HPLC for possible interfering
nucleosides. Supernatants from wells plated initially with 104
target PBLs/well with or without 104 feeder cells/well in NM
or DM in the presence of MTX (100pM) were examined. Hx
(3.17pM) and X (6.45pM) were detected in NM but were
not present in DM. However after 5 days culture super-
natants from MTX treated DM wells which included only
target cells, feeder cells or both, contained measureable Hx
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Figure 2 The effects of target cell number, FBS dialysis and feeder cells on MTX cytotoxicity at day 14 of culture. Microwells
were plated initially with (a) 104 target cells/well or (b) 102 target cells/well in the presence (+) or absence (-) of 100 M MTX
and/or 104 feeder cells/well. Columns, mean ofduplicate cultures. FBS E] normal E dialysed.
and X (Figure 3a,b). TdR was not detected until the day 8
harvest when it was found in all wells (0.3-1.8uM) whether
or not feeders were present or the cultures were in DM
(Figure 3a,b) or NM. The concentrations of TdR and Hx
were lower in cultures with no feeders present.
MTX was cytotoxic to target PBLs plated at 102 cell/well
in DM (Figure 2b). When both TdR 0.1-1.0pM and Hx 0.1
or 1.0MM were added to these cultures MTX cytotoxicity
was reduced. At the higher TdR concentrations, in the
presence of Hx (0.1 or 1.0MM), growth approached that of
control cultures (Figure 4). Neither TdR nor Hx at these
concentrations affected PBL growth in the absence of MTX
(Figure 4), nor individually altered MTX toxicity.
Discussion
We have successfully established the assay for in vivo somatic
cell mutations developed independently by both Morley et al.
(1983, 1985) and Albertini et al. (1982, 1985) using 6-TG as
the selection agent for mutations at the hypoxanthine-
guanine phosphoribosyltransferase locus. However, when
MTX was used as the selecting agent in the assay,
cytotoxicity was not observed (Figure 1). MTX was most
growth inhibitory to cells plated at high initial densities (104
cells/well) even though the cell growth rate was markedly
less in the corresponding control wells than in controls
plated at lower densities. Wells inoculated with 102 cells
initially in MTX increased their cell number 10-fold over the
incubation period. Clearly MTX cytotoxicity was modulated
by some aspect of the culture conditions and the initial
target cell numbers were a crucial determining factor. The
lowered growth rate in control cultures plated at higher
initial densities indicates that the levels of nutrients or
crowding or some other factor affected growth. The number
of viable cells remaining in all wells after extended exposure
to high MTX concentrations could not be attributed to
mutation to resistance alone.
Modulation of MTX cytotoxicity by exogenous thymidine
and purines in mammalian cells is well known. Thymidine
and purine free RPMI-1640 in combination with dialysed
FBS (DM) eliminated all non-cellular sources of these
nucleosides and bases, however growth equivalent to that
in NM was still observed in the presence of MTX if
high plating densities were used (Figure 2a). Although under
these conditions viable cell counts fell rapidly during the first
5 days in 100MuM MTX, a large proportion of remaining
cells continued DNA synthesis and the exclusion of feeder
cells did not eliminate growth. However if the target cell
number was reduced to 102 cells/well MTX was cytotoxic.
It appears that metabolites released by dying target cells
(±feeder cells) protected or rescued remaining viable target
cells from MTX. Presumably these metabolite levels were
not adequate to effect rescue if 102 target cells/well were
plated.
Our HPLC data demonstrate that with time Hx and TdR
appeared at micromolar levels in DM culture supernatants
(Figure 3a, b). The appearance of these purines and pyrimi-
dines may be attributed to the catabolism of nucleic acid
from dead and dying cells. When feeder cells were omitted
from higher density DM cultures, Hx and TdR still appeared
in the medium albeit at lower levels. This observation is
consistent with the hypothesis that dying target cells release
metabolites that rescue viable target cells from antifolate
cytotoxicity and growth inhibition. Our data (Figure 4)
clearly demonstrate that micromolar levels of TdR and Hx
prevent methotrexate cytotoxicity in this lymphocyte clonal
assay, and therefore the cells remaining at the end of the
culture period are PBLs with very efficient nucleoside and
base salvage mechanisms. These salvage mechanisms must be
blocked if this assay is to be used to screen for MTX
resistance due to other mechanisms. A drug known to inhibit
nucleoside transport, such as dipyridamole may be of use.
Sobrero & Bertino (1986) have reported that two factors
determined MTX cytotoxicity to the human colon adeno-
carcinoma cell line HCT-8 in cloning assays: (a) dialysable
protective agents in normal FBS which they identified
indirectly as TdR and Hx and (b) the total cell number
reached in each plate at the end of the culture period. They
recommended that, if normal FBS was used in in vitro assays
assessing drug induced cell death, only colonies representing
> 10 cell divisions should be scored. In our PBL assay viable
cell numbers of this order were observed even when DM was
used but obviously did not arise from one cell. Such an
occurrence in a similar assay may lead to misinterpretation
of data if careful progressive cell counts were not possible.
We have also demonstrated that not only are exogenous and
dialysable sources of protective agents interfering in the
assay but also metabolites released by target cells may
interfere depending on initial target cell plating numbers.
How relevant metabolites released from dying target cells
may be to in vitro assays where agar is used has not so far
a)
.0)
0)
CU
461462 J.M. HUGHES et al.
a
1.2 ,- i0
104
S. > 1
o 0.8 J8
2 4 6 8 10
Incubation (days)
b
CD
0
C
0
0.4
2 5 8 12
Incubation (days)
b
1.2
c
0 0. 6 2 4 6 8 10
Incubation (days)
C a,
0
C
0
0.4
2 5 8
Incubation (days) Fiue3Changes innucleosides and base concentrations in
pooled supernatants from duplicate MTX-treated microwell
cultures plated initially with 104 target cells/well in DM in the
presence (a) or absence (b) of 104 feeder cells/well. Insets: Cell
growth under these conditions: 0, 100,uM MTX; 0, control.
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been extablished. However similar problems have been
reported with the measurement of methotrexate resistance
using soft agar cloning techniques (Cole & Arlett, 1976).
This implies that diffusible catabolites have the capacity to
interfere with colony growth even in agar and may be a
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Figure 4 Modulation of MTX toxicity by a combination of
TdR and Hx. 102 target cells together with 104 feeder cells in
DM were plated/well in the presence ( ) or absence (---)
of 100jM MTX. 0, control; OI, lO,uM Hx; A, 0.5 uM TdR;
*, MTX+l.OM Hx+0.5jiM TdR; A, MTX+1.OM
Hx+0.1I,M TdR. Points, mean of 2 or 3 experiments; bars,
standard error of mean from 3 experiments shown for 0, EO and
* only.
complicating factor in the in vitro chemosensitivity measure-
ments in human tumour stem cell assays. Metabolites from
dying cells may also modulate the cytotoxicity of other
antimetabolites, such as 5-fluorouracil and cytosine
arabinoside when similar culture conditions are utilised.
The possibility must be considered that regional variations
in nucleoside and base concentrations in vivo may modulate
antimetabolite cytotoxicity. It has been demonstrated that
extracellular nucleoside and base concentrations in bone
marrow for instance are substantially greater than in
peripheral plasma (Tattersall et al., 1983). Purines at these
levels have been shown to modulate MTX toxicity in culture
(Taylor et al., 1982). The extracellular purine status within
solid tumours is not well defined but it is known that
hypoxia, which commonly occurs in solid tumours, increases
plasma Hx levels (Saugstad, 1975). Cell death in avascular
areas may also raise the nucleoside and base concentrations
within the tumour microenvironment. For all these reasons
these metabolites may be important determinants of anti-
metabolite toxicity in normal and malignant tissues in vivo.
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